PFAS, Battery Tech And Medical Launches Will Shape Markets

AN
AnalystConsensusTarget
Consensus Narrative from 1 Analyst
Published
08 Apr 25
Updated
24 Jul 25
AnalystConsensusTarget's Fair Value
US$0.35
50.5% undervalued intrinsic discount
24 Jul
US$0.17
Loading
1Y
-30.6%
7D
-3.8%

Author's Valuation

US$0.3

50.5% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on01 May 25

Shared on24 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on17 Apr 25

AnalystConsensusTarget has decreased revenue growth from 10.9% to 8.0%, increased future PE multiple from 71.3x to 82.7x and increased shares outstanding growth rate from 0.0% to 0.0%.